AlenCiken

AlenCiken

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline. finance.yahoo.com

AlenCiken

Savara Announces Pricing of Public Offering of Common Stock $SVRA today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offered to certain existing investors pre-funded warrants to purchase an...

AlenCiken

Large Southwestern Health System Signs New Contract for Streamline Health® eValuator™ $STRM today announced it has signed a contract with a 1,300-bed, Epic EMR-based health system in Arizona. The healthcare provider will use eValuator’s cloud-based automated pre- and post-bill coding analysis technology to help improve revenue integrity for their inpatient and...

AlenCiken

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE) $2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included finance.yahoo.com

AlenCiken

Sunlink Health Systems, Inc. Announces $2 Million Expansion, Capital and Operating Improvements at Trace Regional Hospital announced today that its wholly-owned subsidiary, Trace Regional Hospital, has implemented its Trace Forward Capital Plan totaling approximately $2 million to expand, upgrade and improve its physical plant, patient care, ancillary services...

AlenCiken

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity. RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells...

AlenCiken

Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject...

AlenCiken

Sigma Labs Signs Agreement With Lockheed Martin for Its PrintRite3D(R) In-Process Quality Assurance Solution Sigma Labs has been awarded a contract for an initial system of its PrintRite3D in-process quality assurance solution by Lockheed Martin Space Additive Design & Manufacturing Center based in Sunnyvale, California. finance.yahoo.com

AlenCiken

INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement $INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain...

AlenCiken

Exela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital...

AlenCiken

Ebang International to Commence Beta Testing on March 15, 2021 and Launch Cryptocurrency Exchange by the End of March 2021 Our upcoming cryptocurrency exchange will accelerate the Company's development in the financial technology industry. In addition to establishing a digital asset financial service platform, the Company will also explore other business...

AlenCiken

Adient announces strategic transformation in China - Company enters into agreement with joint venture partner Yanfeng to end its YFAS joint venture - Transactions provide Adient opportunity to independently drive its strategy in China - After-tax proceeds of ~$1.4B, combined with existing cash on the balance sheet, are expected to drive significant debt paydown...

AlenCiken

Shares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday. BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept...

AlenCiken

Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data ‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a...

AlenCiken

NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol) Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S. $NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby...

AlenCiken

$EYES Receives FDA Approval for the Argus 2s Retinal Prosthesis System $EYES today announced U.S. FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company...

AlenCiken

IF you have altcoins i would be very scared, Bitcoin dominance will explode higher and left altcoins behind.

AlenCiken

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome. Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product...